Current Opinion in HIV and AIDS

Papers
(The TQCC of Current Opinion in HIV and AIDS is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission93
Future options for long-acting HIV treatment and prevention65
The sounds of silencing: dynamic epigenetic control of HIV latency46
Updates on bone health in people living with HIV: global impact, prediction tools, and treatment44
HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment31
Harnessing natural killer cells to target HIV-1 persistence28
Statins for primary cardiovascular disease prevention among people with HIV: emergent directions27
Editorial introductions26
Editorial introduction25
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children25
Development of screening assays for use of broadly neutralizing antibodies in people with HIV25
New latency-promoting agents for a block-and-lock functional cure strategy20
A behavioral economics approach to enhancing HIV preexposure and postexposure prophylaxis implementation19
Challenges towards an AIDS-free generation in Africa and Asia19
Editorial introduction19
Loneliness and social isolation in people with HIV19
Editorial introduction18
Persistent elite controllers as the key model to identify permanent HIV remission18
Defining multimorbidity in people with HIV – what matters most?17
The origins of new SARS-COV-2 variants in immuncompromised individuals17
Immunological effector mechanisms in HIV-1 elite controllers17
Hepatitis co-infection in paediatric HIV: progressing treatment and prevention16
Role of follicular homing natural killer cells in HIV infection16
Viral and immune predictors of HIV posttreatment control16
Renal adverse drug reactions15
Editorial introduction15
Impact of coronavirus disease 2019 on co-morbidities in HIV15
The multifaceted nature of HIV tissue reservoirs14
Mpox and the impact on people with HIV13
New vector and vaccine platforms: mRNA, DNA, viral vectors13
Mechanisms and primary prevention of atherosclerotic cardiovascular disease among people living with HIV12
Obesity among women with HIV12
Beyond criminalization: reconsidering HIV criminalization in an era of reform12
Broadly neutralizing antibodies for HIV treatment and cure approaches11
Frailty in people with HIV: a geriatric syndrome approach to aging with HIV11
Gender and sex considerations in HIV and bone health11
Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels11
The severity of COVID-19 across the spectrum of HIV10
Assessing proviral competence: current approaches to evaluate HIV-1 persistence10
Host factors predisposing to kidney disease in people with HIV10
Editorial: New drugs for HIV: quo vadis?10
Strategies to target the central nervous system HIV reservoir10
HIV and cardiovascular disease: the role of inflammation10
Editorial introduction9
HIV drug resistance in various body compartments9
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies8
Persistent HIV-1 transcription during ART: time to reassess its significance?8
Causes and outcomes of hepatic fibrosis in persons living with HIV8
Editorial introduction7
Vaccinal effect of HIV-1 antibody therapy: dream or reality?7
Editorial introductions7
Innovative models of care supporting people aging with HIV7
Editorial introductions6
Guiding HIV-1 vaccine development with preclinical nonhuman primate research6
HIV-1 subtypes and latent reservoirs6
Editorial: Is it time to implement injectable antiretroviral treatments globally?6
The pathogenesis of obesity in people living with HIV6
Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here?6
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development6
The innovative use of qualitative and mixed methods research to advance improvements along the HIV prevention and care continua5
Editorial introductions5
Scaling up preexposure prophylaxis to maximize HIV prevention impact5
Whole person HIV services: a social science approach5
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?5
Stem cell transplantation and allogeneic immunity: post treatment control or HIV cure?5
HIV and comorbidities – the importance of gut inflammation and the kynurenine pathway5
Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review5
Towards a molecular profile of antiretroviral therapy-free HIV remission5
Role of islatravir in HIV treatment and prevention: an update5
Towards an HIV cure: one cell at a time5
0.05386209487915